US Stock MarketDetailed Quotes
MAIA MAIA Biotechnology
- 2.980
- -0.020-0.67%
Close Aug 23 16:00 ET
- 2.730
- -0.250-8.39%
Post 20:02 ET
71.24MMarket Cap-1839P/E (TTM)
3.040High2.880Low57.22KVolume3.010Open3.000Pre Close171.66KTurnover0.29%Turnover RatioLossP/E (Static)23.91MShares5.99052wk High22.58P/B58.06MFloat Cap0.82052wk Low--Dividend TTM19.48MShs Float9.640Historical High--Div YieldTTM5.33%Amplitude0.820Historical Low3.000Avg Price1Lot Size
MAIA Biotechnology Stock Forum
Sign in to post a comment
So ive been asked by quite a few people that are newer traders! And because of being where we all have been. They are learning charts and where to enter and exit on momentum / day trades. But having a bit of trouble. Again as we all did and at times still do. Most know that because i cant know others risk tolerance. Or the type of trade they are doing? That i do not give buy / sell advice. But i was asked could i give some swing trade ideas, so they could have a chance to ...
34
7
$MAIA Biotechnology (MAIA.US)$
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
MAIA Biotechnology (NYSE American: MAIA) has announced positive updates from its Phase 2 THIO-101 trial, evaluating THIO sequenced with cemiplimab in advanced non-small cell lung cancer (NSCLC) patients who failed multiple standard therapies. Key highlights include:
1. Six patients have continued treatment for over 12 months, completing up to 21 cycles.
2. The THIO-cemipl...
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
MAIA Biotechnology (NYSE American: MAIA) has announced positive updates from its Phase 2 THIO-101 trial, evaluating THIO sequenced with cemiplimab in advanced non-small cell lung cancer (NSCLC) patients who failed multiple standard therapies. Key highlights include:
1. Six patients have continued treatment for over 12 months, completing up to 21 cycles.
2. The THIO-cemipl...
$MAIA Biotechnology (MAIA.US)$ MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.
$MAIA Biotechnology (MAIA.US)$ Maia Biotechnology Inc - Maia's Phase 2 Thio-101 Clinical Trial Is Expected to Near Completion in 2024
$MAIA Biotechnology (MAIA.US)$ Check that uptrend since the PP i posted the PR on March 12! Lovely just lovely! Hehehe![]()
2
$MAIA Biotechnology (MAIA.US)$ Maia Biotechnology Inc - Anticipate Full Efficacy Data From Thio-101 in Second Half of This Year
2
1
$MAIA Biotechnology (MAIA.US)$ MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
1 MINUTE AGO, 8:41 AM EDT
VIA BUSINESSWIRE
1 MINUTE AGO, 8:41 AM EDT
VIA BUSINESSWIRE
1
$MAIA Biotechnology (MAIA.US)$
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
MAIA Biotechnology announced new data from its Phase 2 THIO-101 clinical trial, showing promising results for the drug THIO when combined with cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC) patients who have failed 2 or more standard-of-care therapies. The trial reports a favorable overall response rate (ORR) of 38% and a disease contro...
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
MAIA Biotechnology announced new data from its Phase 2 THIO-101 clinical trial, showing promising results for the drug THIO when combined with cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC) patients who have failed 2 or more standard-of-care therapies. The trial reports a favorable overall response rate (ORR) of 38% and a disease contro...
2
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
14
3
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Jenna Ragan : RIGL!! RIGL!!![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Jenna Ragan : Hehehe! Yes ma’am pretty lady! I just knew that one would get you attention! Hehehe. Thanks for the smile you just gave me! Hehehe![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Jenna Ragan Trytosaveabit OP : You are very welcome![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Seraphicall : CMMB yes.
but you have these many holdings?
MARKET-TEST-DUMMY : I want to say thank you because it takes time to research this information. Your very kind for sharing.
A true gentleman and scholar!
View more comments...